Syndax Pharmaceuticals, Inc. (SNDX) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

22/25

Growth 5 Margin 5 Expansion 5 Platform 3 Financial 4

latest quarter score

Earnings Reports

22
Syndax (SNDX) Q2 2026: Revuforge Treatment Duration Climbs Beyond 9 Months, Fueling Recurring Revenue Base
August 05, 2026
23
Syndax (SNDX) Q1 2026: Revuforge Drives 224% Revenue Surge, Transplant Tailwind Set to Accelerate
May 01, 2026
20
Syndax (SNDX) Q4 2025: Revuforge Net Revenue Climbs 38% on Expanded AML Penetration
February 27, 2026
24
Syndax (SNDX) Q3 2025: Revuforge Scripts Jump 25% as NPM1 Approval Triples Addressable Market
November 04, 2025
Syndax (SNDX) Q2 2025: Revuforge Sales Jump 43% as Early-Line Adoption Drives Multi-Year Upside
August 05, 2025
13
Syndax (SNDX) Q1 2025: Revuforge Orders Hit 44% of Priority Accounts, Fueling Commercial Ramp
July 07, 2025
Syndax Pharmaceuticals (SNDX) Q4 2024: $7.7M Revuforj Launch Revenue Signals Oncology Commercial Breakthrough
March 03, 2025

Browse all companies